(Q26998392)

Jonathan Strosberg

series ordinal

2

1 reference

Eric Baudin

series ordinal

3

1 reference

James C. Yao

series ordinal

5

1 reference

language of work or name

1 reference

15 September 2014

1 reference

1 reference

120

1 reference

issue

18

1 reference

page(s)

2814-23

1 reference

The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Clinical and therapeutic aspects of extrapulmonary small cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Extrapulmonary small cell carcinoma: single center experience with 61 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Should extrapulmonary small cell cancer be managed like small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Small-cell carcinomas of the gastrointestinal tract: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Rare tumors of the colon and rectum: a national review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Genetic alterations in poorly differentiated endocrine colon carcinomas developing in tubulo-villous adenomas: a report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Are neuroendocrine tumors going mainstream?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Neuroendocrine carcinomas of the colon and rectum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Consensus guidelines for the management and treatment of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

Extrapulmonary small cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Genetic evidence for the multi-step progression of mixed glandular-neuroendocrine gastric carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28721

7 January 2021

Identifiers

DOI

10.1002/CNCR.28721

0 references

PubMed publication ID

24771552

1 reference